Genetic variants in the USF1 gene are associated with low-density lipoprotein cholesterol levels and incident type 2 diabetes mellitus in women: results from the MONICA/KORA Augsburg case–cohort study, 1984–2002

C Holzapfel 1,2, J Baumert 1, H Grallert 1, A M Müller 1,3, B Thorand 1, N Khuseyinova 4, C Herder 5, C Meisinger 1, H Hauner 2, H E Wichmann 1,3, W Koenig 4, T Illig 1 and N Klopp 1

1Institute of Epidemiology, Helmholtz Center Munich, German Research Center for Environmental Health, Ingolstädter Landstraße 1, D-85764 Neuherberg, Germany, 2Else Kröner-Fresenius-Center for Nutritional Medicine, Technical University of Munich, Munich, Germany, 3Institute of Medical Information Processing, Biometry and Epidemiology, Chair of Epidemiology, Ludwig-Maximilians-University, Munich, Germany, 4Department of Internal Medicine II-Cardiology, University of Ulm Medical Center, Ulm, Germany and 5Institute for Clinical Diabetes Research, German Diabetes Center, Leibniz Institute at Heinrich-Heine-University, Düsseldorf, Germany

(Correspondence should be addressed to N Klopp; Email: klopp@helmholtz-muenchen.de)

Abstract

Objective: Upstream transcription factor 1 (USF1) regulates genes of glucose and lipid metabolism. Polymorphisms in the USF1 gene showed association with familial combined hyperlipidemia and lipid parameters. The aim of our study was to examine the associations between USF1 polymorphisms and lipid parameters as well as incident type 2 diabetes mellitus (T2DM) in German Caucasians.

Design: We genotyped eight polymorphisms in the USF1 gene in 2067 middle-aged (35–74 years) individuals including 498 incident T2DM cases and 1569 non-cases of the population-based case–cohort study from the MONICA/KORA Augsburg project.

Methods: Six polymorphisms and their haplotypes were analyzed using multivariable linear regression and Cox proportional hazards models.

Results: Polymorphism rs3737787 was inversely associated with incident T2DM in women with decreased risk for female heterozygotes compared with women homozygous for the major allele (Hazard ratio = 0.57; 95% confidence intervals: 0.38–0.87; P = 0.008). After correction for multiple testing, significance remained. Polymorphisms rs3813609 and rs1556259 were significantly associated with reduction in low-density lipoprotein (LDL) cholesterol (pNOM = 0.001; pNOM = 0.00002) in women. Analyses also indicated associations of haplotypes with LDL cholesterol in women, but the association lost statistical significance after correction for multiple testing. Total serum cholesterol (TC) and high-density lipoprotein (HDL) cholesterol were weakly associated (P < 0.05) with USF1 polymorphisms in women. No significant associations were found in men.

Conclusions: In this large population-based study, statistically significant associations of USF1 polymorphisms with incident T2DM and LDL cholesterol were found in women, but not in men. Genetic variants in the USF1 gene showed weak or no associations with TC and HDL cholesterol.

Introduc
expression of insulin by interacting with the enhancer of the insulin gene (14) and has been reported to affect the expression of the islet-specific glucose-6-phosphatase catalytic subunit-related protein (15).

Taking into account the central role of USF1 in glucose and lipid metabolism as well as the results of recent association studies, it could be assumed that the USF1 gene represents an attractive candidate gene, which might contribute to lipid disturbances and type 2 diabetes mellitus (T2DM). USF1 is associated with familial combined hyperlipidemia (FCHL) (16–18), diabetes mellitus (T2DM), and total serum cholesterol (TC), a phenotypic overlap between FCHL, T2DM, and the metabolic syndrome exists (19, 20).

In some studies (18, 21–24), genetic variants within the USF1 gene showed associations with serum triglycerides, whereas in two US cohort studies of cardiovascular disease risk (25), in French Caucasians (26), and in Korean adults (27), no associations with serum triglycerides were observed.

Also for low-density lipoprotein (LDL) cholesterol and polymorphisms within the USF1 gene, significant associations were described. In Finnish FCHL families, haplotypes of the single nucleotide polymorphisms (SNPs) rs3737787 and rs2073658 were associated with small LDL peak particle size (21). In the Coronary Artery Risk Development in Young Adults cohort, rs3737787 was associated with lower and rs2516837 with higher LDL cholesterol levels, whereas no associations were found in the Cardiovascular Health Study (25). In Dutch families, rs3737787 was significantly associated with TC in men, in Utah families not rs3737787, but three other SNPs were associated with TC (18, 24). In US Whites suffering from coronary artery disease (CAD), no association with TC was found (18).

The latest result was confirmed by Reiner et al. in a US cohort study and by Gibson et al. in a French study (25, 26). Also, no associations with high-density lipoprotein (HDL) cholesterol were found (24, 25, 27).

Several studies have reported a lack of association between USF1 polymorphisms and glucose parameters or diabetes (18, 24, 25), whereas in US Whites and in Swedish men, associations with glucose levels were observed (18, 28). Also in haplotype analyses, associations with peak of glucose were found (29).

Considering the existing controversial results on the associations between USF1 gene and lipids and T2DM, the aim of the present study was to determine whether genetic variants in the USF1 gene are associated with the lipid parameters such as TC, LDL, and HDL cholesterol as well as with incident T2DM in a large prospective population-based case–cohort study from southern Germany. Therefore, eight SNPs within the USF1 gene and their haplotypes were investigated in the case–cohort study of the Monitoring of Trends and Determinants in Cardiovascular Disease/Cooperative Health Research in the Region of Augsburg (MONICA/KORA) project. Because of sex-specific dissimilarities in the development of T2DM (30–32) and sex-specific results concerning USF1 polymorphisms and lipid parameters, there was a separate analysis for men and women (18, 21, 23).

Subjects and methods

Study design

The MONICA/KORA Augsburg study (1984–2002) is a population-based study of adults with German nationality (33). As part of the international World Health Organization MONICA project, three independent cross-sectional population-based surveys (S1–S3) covering the city of Augsburg and two adjacent counties were conducted in 1984/1985 (S1), 1989/1990 (S2), and 1994/1995 (S3) to estimate the prevalence and distribution of cardiovascular risk factors among men and women aged 25–64 (S1) or 25–74 years (S2 and S3). The surveys included a standardized interview and clinical investigations and were approved by the local ethic authorities including genetic analyses for cardiovascular and metabolic diseases. The total number of participants was 13 427 (6 725 men and 6 702 women). All subjects were prospectively followed within the framework of the KORA Augsburg project (34).

The incidence of T2DM was assessed using a written follow-up questionnaire sent to all participants of the three baseline surveys in 1997/1998 and 2002/2003. Furthermore, all S1 participants were invited to a follow-up examination in 1987/1988. Cases with self-reported incident diabetes were validated by a questionnaire mailed to the treating physician or medical chart review. Only subjects for whom the treating physician clearly reported a diagnosis of T2DM or for whom a diagnosis of T2DM was mentioned in the medical records or who were taking anti-diabetic medication were classified as T2DM cases for the present analysis. Owing to the low incidence of T2DM in younger subjects, the present study was limited to 10 718 persons (5382 men and 5336 women) aged 35–74 years at baseline. After exclusion of 1187 subjects with missing blood samples and 1595 participants with prevalent T2DM, with incident diabetes other than T2DM (e.g., type 1 or secondary diabetes), with self-reported, but non-validated incident diabetes, without follow-up information or with a follow-up time of less than 1 year, the source population of the present study comprised 7936 subjects (3894 men and 4042 women).

On this source population, we applied a case–cohort study consisting of a random sample (called sub-cohort; n = 1885) of the source population stratified by sex and survey, and all incident T2DM cases (n = 555) in the source population diagnosed up to December
31, 2002 as it was described more detailed previously (31, 35–37).

After the exclusion of subjects with missing DNA samples and missing values for lifestyle or metabolic risk factors, the present study including the subcohort and incident T2DM cases was based on 2067 participants (307 men and 191 women with incident T2DM; 835 men and 734 women without incident T2DM). Mean follow-up time (± s.d.) was 10.1 (± 4.9) years. The final stratum-specific sample sizes of the subcohort were used together with the stratum-specific sizes of the source population to compute sampling fractions, and the inverse of the sampling fractions yielded survey- and sex-specific sampling weights.

All cross-sectional analyses concerning SNP frequencies, tests for deviation from Hardy–Weinberg equilibrium (HWE) and associations of SNPs and lipid parameters were performed in random sample (subcohort) of the whole study population with available DNA (i.e., without prior to exclusion of subjects without follow-up information, prevalent diabetes). This sample included 1968 subjects.

Assessment of demographic, lifestyle, and clinical characteristics

Standardized interviews were conducted by trained medical staff (mainly nurses) to assess information concerning sociodemographic variables, smoking habits, leisure time physical activity level, and alcohol consumption. In addition, participants underwent a standardized medical examination and a non-fasting venous blood sample was obtained. Body weight was measured in light clothing by trained investigators to the nearest 0.1 kg, and height to the nearest 0.5 cm. The body mass index (BMI; kg/m²) was calculated by body weight in kg divided by squared body height in m. TC and HDL cholesterol were measured by the Boehringer CHOD-PAP (Roche Diagnostics) and by the phosphotungstic acid method (Boehringer) respectively. After precipitation with dextran sulfate (Quantolip LDL, Immuno AG, Vienna, Austria), LDL cholesterol was measured by the Boehringer CHOD-PAP (Roche Diagnostics) and by the phosphotungstic acid method (Boehringer) respectively. After precipitation with dextran sulfate (Quantolip LDL, Immuno AG, Vienna, Austria), LDL cholesterol was determined. All survey methods have been described elsewhere in detail (30).

Selection of polymorphisms

For SNP selection, the NCBI SNP database (www.ncbi.nlm.nih.gov) and the Haplootype Mapping (HapMap) database (www.hapmap.org) were used. In addition, a literature search was performed. Eight polymorphisms (Fig. 1; Table 1) were selected for genotyping and, according to high correlation (linkage disequilibrium (LD), $r^2 \geq 0.8$), six tagging SNPs were identified. Polymorphisms with a minor allele frequency (MAF) below 10% were not included in the genotyping process due to power calculation. The selected SNPs completely cover the common genetic variation (SNPs with MAF greater 10%) in the USF1 gene and flanking regions. Polymorphisms rs1556259, rs2516839, rs2774276, rs2073658, and rs3737787 are located in introns and exons of the USF1 gene, rs3813609 and rs2774279 in the 5′ region (ARHGAP30 gene) and rs10908821 in the 3′ region (F11R gene) of the USF1 gene.

Genotyping

DNA samples were genotyped with the MassARRAY system using the iPLEX chemistry (Sequenom, San Diego, CA, USA). The allele-dependent primer extension products were loaded onto one 384 element chip using a nanoliter pipetting system (SpectroCHIP, SpectroPOINT Spotter, Sequenom). The samples were analyzed in a matrix-assisted laser desorption ionization time of flight mass spectrometer (MALDI TOF MS: Bruker Daltonik, Leipzig, Germany). The resulting mass spectra were analyzed automatically for peak identification via the SpectroTYPE RT 3.4 software (Sequenom). For quality reasons, 10% of the spectra were checked independently by two investigators. Negative controls were included in all assays. To control for reproducibility of genotyping data, 12.5% of randomly selected samples were genotyped in duplicate. Each SNP was tested for deviation from HWE by means of a χ²-test or Fisher’s exact test depending on allele frequency.

Statistical analysis

Means or proportions for baseline demographic and clinical characteristics of the study population were computed using the statistical analysis system (SAS) procedures, SURVEYREG or SURVEYFREQ, which estimate s.e.m. appropriate to the sampling scheme. Tests of differences between subjects with and without incident T2DM were based on these procedures. Associations between USF1 polymorphisms or haplotypes and lipid...
parameters were assessed separately for men and women by linear regression analysis using SURVEYREG with adjustment for age and survey.

Cox proportional hazards regression was used to assess the association between polymorphisms or haplotypes and incident T2DM. To account for the case–cohort design, S.E.M.S were corrected using the ‘sampling weight’ approach developed by Barlow (38). Since sex-related differences seem to play a role in the development of diabetes, all analyses were done separately for men and women and carried out for each USF1 SNP with a multivariable-adjusted model, including survey, age, BMI, systolic blood pressure, ratio of TC:HDL cholesterol, smoking status (never smoker, former smoker, and current smoker), alcohol consumption (men 0, 0.1–39.9, ≥ 40 g/day; women 0, 0.1–19.9, ≥ 20 g/day), and physical activity (inactive versus active, i.e., regular physical activity of ≥ 1 h/week in both summer and winter). P values are based on robust variance estimates using the Barlow approach. For each USF1 SNP, we assumed that a nominal model and tests were carried out based on this model using ANOVA (with two degrees of freedom) with P values denoted as $P_{\text{NOM}}$. Additionally, a test based on an additive model was performed to assess the association between each USF1 SNP and incident T2DM ($P$ values denoted as $P_{\text{ADD}}$).

As measures for pairwise LD between SNPs, Lewontin’s disequilibrium coefficient $D’$ and the squared correlation coefficient $r^2$ were calculated. A correlation coefficient of $r^2 \geq 0.8$ was classified as high correlation. Haplotype reconstruction was performed within blocks of high $D’$ between consecutive SNPs ($D’ \geq 0.8$) using the expectation–maximation algorithm within the SAS procedure HAPLOTYPE. To avoid large reconstruction errors, haplotype estimation is based only on subjects with complete genotype information. Haplotypes with frequencies below 5% were collected into a separate group of rare haplotypes. All haplotypes with frequency higher than 5% and the rare group were analyzed in a multivariable model with the most frequent haplotype as reference assuming an additive model.

The global significance level of 5% was corrected for the number of independent tests following the Bonferroni procedure. The number of independent tests was calculated as the number of effective loci ($n = 5$) obtained through spectral decomposition of the correlation matrix of all SNPs analyzed in approach to Li & Ji (39).

Haplotype analyses, $\alpha = 0.003$ (lipids) or $\alpha = 0.01$ (T2DM) was statistically significant. Power estimation for the case–cohort study was performed by the method of Cai & Zeng (40). All statistical analyses were performed using the statistical package SAS Version 9.1 (SAS Institute, Cary, NC, USA).

### Results

#### Description

Baseline characteristics of the MONICA/KORA Augsburg case–cohort study participants are given in Table 2. Compared with subjects without incident T2DM, cases were older with a mean age of 56.0 years (non-cases: 51.6 years), showed higher BMI values with a mean BMI of 30.0 kg/m² (non-cases: 26.7 kg/m²), and had a higher waist-to-hip ratio (0.927; non-cases: 0.864). Also concerning blood pressure, hypertension, and myocardial infarction, cases and non-cases differed significantly. Furthermore, significant differences were observed between the two study groups with respect to lipid parameters such as TC, LDL, and HDL cholesterol. Indeed, T2DM cases demonstrated significantly increased concentrations of TC (247.4 mg/dl; non-cases: 235.9 mg/dl) and LDL cholesterol (158.2 mg/dl; 410 C Holzapfel and others

### Table 1 Characteristics of the upstream transcription factor 1 (USF1) polymorphisms genotyped in MONICA/KORA Augsburg case–cohort study population.

<table>
<thead>
<tr>
<th>SNP no.</th>
<th>Gene position (dbSNP build 126)</th>
<th>MAF (in our subcohort)</th>
<th>HWE</th>
<th>Success rate</th>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>rs3813609*</td>
<td>5’ flanking region</td>
<td>$G$ = 0.38</td>
<td>0.93</td>
<td>98.5</td>
<td>38.5</td>
<td>47.2</td>
<td>14.4</td>
</tr>
<tr>
<td>rs2774279</td>
<td>5’ flanking region</td>
<td>$T$ = 0.33</td>
<td>0.48</td>
<td>96.4</td>
<td>45.3</td>
<td>43.6</td>
<td>11.1</td>
</tr>
<tr>
<td>rs1556259</td>
<td>Intron 1</td>
<td>$C$ = 0.13</td>
<td>0.48</td>
<td>96.7</td>
<td>76.7</td>
<td>21.6</td>
<td>1.7</td>
</tr>
<tr>
<td>rs2516839*</td>
<td>Exon 2</td>
<td>$G$ = 0.38</td>
<td>0.86</td>
<td>96.7</td>
<td>38.5</td>
<td>47.3</td>
<td>14.2</td>
</tr>
<tr>
<td>rs2774276</td>
<td>Intron 5</td>
<td>$C$ = 0.25</td>
<td>0.60</td>
<td>98.2</td>
<td>56.0</td>
<td>37.3</td>
<td>6.6</td>
</tr>
<tr>
<td>rs2073658**</td>
<td>Intron 7</td>
<td>$A$ = 0.28</td>
<td>0.04</td>
<td>96.5</td>
<td>53.0</td>
<td>38.5</td>
<td>8.5</td>
</tr>
<tr>
<td>rs3737787**</td>
<td>Exon 11 (3’-UTR)</td>
<td>$T$ = 0.29</td>
<td>0.87</td>
<td>98.4</td>
<td>50.5</td>
<td>41.0</td>
<td>8.5</td>
</tr>
<tr>
<td>rs10908821</td>
<td>3’ flanking region</td>
<td>$G$ = 0.13</td>
<td>0.47</td>
<td>97.2</td>
<td>75.4</td>
<td>22.6</td>
<td>2.0</td>
</tr>
</tbody>
</table>

For every SNP gene position, minor allele frequency (MAF), $P$ value of Hardy–Weinberg equilibrium (HWE), genotyping success rate (%), and the genotype frequencies (0, homozygous in major allele; 1, heterozygous; 2, homozygous in minor allele; %) weighted for the sampling scheme are given; **SNP rs3813609 and rs2516839 as well as ***SNP rs2073658 and rs3737787 are highly correlated ($r^2 \geq 0.8$).
Clinical Survey

Eight polymorphisms (rs3813609, rs2774279, rs1556259, rs2516839, rs2774276, rs2073658, rs3737787, and rs10908821) within the USF1 gene and its flanking regions were successfully genotyped with a mean genotyping success rate of about 97%. Seven SNPs fulfilled the assumption of HWE (P > 0.05), whereas rs2073658 revealed a slight deviation from HWE with a P value of 0.04. This polymorphism, however, was highly correlated with rs3737787 ($r^2 = 0.99$; $D^2 = 1.0$). The MAF and genotype frequencies as well as the characteristics of all SNPs are shown in Table 1. For statistical analyses, one representative polymorphism per LD block ($r^2 \geq 0.8$) was selected. The chosen SNPs were those with the best genotyping success rates per LD block. Haplotype reconstruction following the reading direction of the gene revealed five haplotypes with a frequency of more than 5%: GTTGCC (33.1%), GCTGTC (28.6%), CCTCCG (13.0%), CCGGCC (12.9%), and CCTCCC (11.8%; data not shown).

**Association of USF1 SNPs and haplotypes with incident T2DM**

In the present study, a significant association was detected only between one analyzed polymorphism within the USF1 gene and incident T2DM. SNP rs3737787 was inversely associated with incident T2DM in heterozygous women compared with women who were homozygous carriers of the major allele (Hazard ratio (HR) = 0.57; 95% confidence intervals (CI): 0.38–0.87; P = 0.008) after correction for multiple testing (Table 3). In men, no significant associations were found between USF1 SNPs and incident T2DM.

We performed two sensitivity analyses to confirm our results. Additional adjustment for lipid lowering or anti-hypertensive medication and intake of statins as well as intake of oral contraceptive and HRT did not confound substantially the associations between SNPs and incident T2DM. Following this adjustment, the effect of the heterozygote genotype of rs3737787 on the risk for incident T2DM was 0.61 (95% CI: 0.40–0.92; P = 0.020) compared with the homozygote genotype with the major allele. However, this association remained not significant after correction for multiple testing. Moreover, the adjustment for glucose, HbA1c, and triglycerides (only available in S3, 262 men with 67 cases, and 249 women with 52 cases) did not change the results in a significant way. The effect of the heterozygote genotype of rs3737787 on the risk for incident T2DM was 0.30 (95% CI: 0.10–0.87) with P value 0.035 compared with the genotype homozygote for the major allele. This association lost statistical significance after correction for multiple testing.

Haplotype analysis did not show any significant association with incident T2DM in men and women (data not shown). Assuming a HR of 1.5, the power to detect a significant difference was over 90% in men and almost 80% in women when the frequency of the genotype with at least one minor allele is assumed to be

<table>
<thead>
<tr>
<th>Variable</th>
<th>T2DM cases</th>
<th>T2DM non-cases</th>
<th>P value$^a$</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Demographic</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number (women/men)</td>
<td>191/307</td>
<td>734/835</td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>56.0 (0.4)</td>
<td>51.6 (0.3)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Education &lt; 12 years</td>
<td>81.7</td>
<td>74.8</td>
<td>0.001</td>
</tr>
<tr>
<td><strong>Clinical</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td>30.0 (0.2)</td>
<td>26.7 (0.1)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Waist to hip ratio</td>
<td>0.927 (0.005)</td>
<td>0.864 (0.003)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg)</td>
<td>142.2 (0.8)</td>
<td>132.7 (0.5)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Diastolic blood pressure (mmHg)</td>
<td>85.3 (0.5)</td>
<td>81.5 (0.3)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>History of actual hypertension</td>
<td>66.5</td>
<td>39.8</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>History of myocardial infarction</td>
<td>5.0</td>
<td>1.9</td>
<td>0.003</td>
</tr>
<tr>
<td>Total cholesterol (mg/dl)</td>
<td>247.4 (2.0)</td>
<td>235.9 (1.1)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>LDL cholesterol (mg/dl)$^b$</td>
<td>158.2 (2.4)</td>
<td>145.8 (1.3)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>HDL cholesterol (mg/dl)</td>
<td>47.9 (0.6)</td>
<td>57.6 (0.4)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>Lifestyle</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smoking status</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current smoker</td>
<td>30.2</td>
<td>24.2</td>
<td>0.022</td>
</tr>
<tr>
<td>Former smoker</td>
<td>33.3</td>
<td>27.2</td>
<td></td>
</tr>
<tr>
<td>Never smoker</td>
<td>38.9</td>
<td>48.6</td>
<td></td>
</tr>
<tr>
<td>Frequency of exercise</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inactive</td>
<td>69.1</td>
<td>58.3</td>
<td></td>
</tr>
<tr>
<td>Active</td>
<td>30.9</td>
<td>41.7</td>
<td></td>
</tr>
<tr>
<td>Alcohol consumption$^d$</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0 g/day</td>
<td>32.1</td>
<td>28.5</td>
<td></td>
</tr>
<tr>
<td>&gt; 0–39.9 g/day</td>
<td>39.4</td>
<td>44.6</td>
<td></td>
</tr>
<tr>
<td>≥ 40 g/day</td>
<td>28.5</td>
<td>26.9</td>
<td></td>
</tr>
<tr>
<td>Current HRT</td>
<td>8.8</td>
<td>12.5</td>
<td>0.219</td>
</tr>
<tr>
<td>Current use of OC$^g$</td>
<td>9.1</td>
<td>14.8</td>
<td>0.238</td>
</tr>
<tr>
<td>Survey</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>S1</td>
<td>36.5</td>
<td>28.9</td>
<td></td>
</tr>
<tr>
<td>S2</td>
<td>39.4</td>
<td>36.1</td>
<td></td>
</tr>
<tr>
<td>S3</td>
<td>24.1</td>
<td>35.0</td>
<td></td>
</tr>
</tbody>
</table>

Data are weighted percentages for categorical variables and weighted means (± S.E.M.) for normally distributed continuous variables; mean follow-up, 10.1 years (± 4.9); weights: cases = 1; non-cases = 1/sampling fraction with sampling fraction = subcohort/full cohort without cases for each sex and survey; hormone replacement therapy (HRT); oral contraceptive (OC).

$^a$Test for continuous variables and $\chi^2$-test for categorical variables.

$^b$Only measured in participants of S2 and S3 (n = 1281).

$^c$Only measured in participants of S2 and S3 (n = 1287).

$^d$Regular physical activity of ≥ 1 h/week in both summer and winter.

$^e$Men: 0 g/day, > 0–39.9 g/day, ≥ 40 g/day; women: 0 g/day, > 0–19.9 g/day, ≥ 20 g/day.

$^f$Only for women aged ≥ 50 years with no current use of OC (n = 538).

$^g$Only for women aged < 50 years with no current HRT (n = 375).

non-cases: 145.8 mg/dl) as well as significantly decreased HDL cholesterol (47.9 mg/dl; non-cases: 57.6 mg/dl) values than non-cases (Table 2). The differences for lifestyle factors such as smoking status, frequency of exercise, alcohol consumption, hormone replacement therapy (HRT), and current use of oral contraceptives are also shown in Table 2.
Three polymorphisms were associated with decreased TC.

**Association of USF1 SNPs and haplotypes with TC, HDL, and LDL cholesterol**

For two lipid markers, TC and HDL cholesterol, significant associations with *USF1* SNPs were observed in women. Three polymorphisms were associated with decreased TC (rs3813609: \( P_{\text{NOM}} = 0.020; \) rs2774276: \( P_{\text{NOM}} = 0.010; \) rs10908821: \( P_{\text{NOM}} = 0.011) and one polymorphism with elevated HDL cholesterol (rs1556259: \( P_{\text{NOM}} = 0.016).\)

None of the analyzed genetic variants was significantly associated with these lipid parameters in men. After correction for multiple testing, none of the associations with TC and HDL cholesterol in women remained significant (Table 4). Also in haplotype analysis, no significant association was found with TC and HDL cholesterol (data not shown).

Several USF1 polymorphisms showed statistically significant associations with decreased LDL cholesterol concentrations in women, but not in men (Table 4). For instance, the association between the intronic polymorphism rs1556259 and reduction in LDL cholesterol concentrations in the nominal model remained significant even after accounting for multiple testing (\( P_{\text{NOM}} = 0.00002; \) \( p(\text{TC}) = 0.085; \) \( p(\text{CC}) < 0.0001).\) Monotone changes in LDL cholesterol levels with increasing number of copies of the minor allele indicate a possible additive effect. Assuming an additive model, the association of rs1556259 remained significant (\( P_{\text{ADD}} = 0.021).\)

Furthermore, rs3813609 located in the 5′ flanking region, and rs2774276 within intron 5 of the *USF1* gene were significantly associated with decreased LDL cholesterol (\( P_{\text{NOM}} = 0.001 \) and \( P_{\text{NOM}} = 0.006 \) respectively: Table 4). The corresponding \( P \) values were 0.224 and 0.0002 for GC and CC genotypes of polymorphism rs3813609 respectively and 0.691 and 0.002 for GC and CC genotypes of polymorphism rs2774276 respectively. Similar to the polymorphism rs1556259, the association between rs3813609 or rs2774276 and decreased LDL cholesterol were also significant in the additive model (\( P_{\text{ADD}} = 0.001; \) \( P_{\text{ADD}} = 0.045).\) All significant associations with LDL cholesterol were detected only in women. After correction for multiple testing, the only associations between rs1556259 and rs3813609 and LDL cholesterol concentrations remained statistically significant (\( P \leq 0.003)\) in the nominal model and rs3813609 also in the additive model (Table 4).

Additional adjustment for BMI, smoking status, alcohol consumption, physical activity, systolic blood pressure, lipid lowering medication, anti-hypertensive treatment, and intake of statins as well as intake of oral contraceptive and HRT in women revealed similar associations between SNPs and mean lipid markers in comparison with models adjusted only for age and survey.

Haplotype analyses revealed that haplotypes CCGGCC and CCTCCC were borderline significantly associated with reduction in LDL cholesterol concentrations (\( P = 0.017 \) and \( P = 0.040 \) respectively), compared with the most frequent haplotype GTTGGC in women, but not in men (data not shown). Both of these haplotypes are observed with frequency of more than 10%. The association, however, was strongly attenuated and was no longer statistically significant after correction for multiple testing.

**Discussion**

In this case–cohort study, none of the analyzed USF1 polymorphisms showed consistent association with...
Table 4 Sex-specific association of polymorphisms within the upstream transcription factor 1 (USF1) gene and the lipid parameters total cholesterol (TC), high-density lipoprotein (HDL), and low-density lipoprotein (LDL) cholesterol.

<table>
<thead>
<tr>
<th>SNP no.</th>
<th>Genotype</th>
<th>N (men)</th>
<th>Mean ± s.e.m.</th>
<th>P value nominal</th>
<th>P value additive</th>
<th>N (women)</th>
<th>Mean ± s.e.m.</th>
<th>P value nominal</th>
<th>P value additive</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total cholesterol</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs3813609</td>
<td>GG</td>
<td>393</td>
<td>235.4 ± 2.3</td>
<td>0.507</td>
<td>0.907</td>
<td>359</td>
<td>243.6 ± 2.3</td>
<td>0.020</td>
<td>0.029</td>
</tr>
<tr>
<td></td>
<td>GC</td>
<td>490</td>
<td>238.3 ± 2.1</td>
<td>419</td>
<td>242.0 ± 2.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CC</td>
<td>170</td>
<td>234.5 ± 3.2</td>
<td>107</td>
<td>232.1 ± 3.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>TT</td>
<td>111</td>
<td>234.7 ± 4.5</td>
<td>104</td>
<td>247.2 ± 4.7</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs2774279</td>
<td>GG</td>
<td>586</td>
<td>235.7 ± 1.9</td>
<td>0.182</td>
<td>0.882</td>
<td>515</td>
<td>242.0 ± 2.0</td>
<td>0.010</td>
<td>0.155</td>
</tr>
<tr>
<td></td>
<td>GC</td>
<td>391</td>
<td>239.6 ± 2.2</td>
<td>319</td>
<td>242.7 ± 2.4</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CC</td>
<td>73</td>
<td>230.5 ± 5.1</td>
<td>49</td>
<td>227.2 ± 4.7</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs3737787</td>
<td>GG</td>
<td>551</td>
<td>237.4 ± 1.9</td>
<td>0.376</td>
<td>0.297</td>
<td>427</td>
<td>240.2 ± 2.0</td>
<td>0.827</td>
<td>0.578</td>
</tr>
<tr>
<td></td>
<td>GC</td>
<td>418</td>
<td>237.1 ± 2.3</td>
<td>376</td>
<td>242.0 ± 2.2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CC</td>
<td>86</td>
<td>229.5 ± 5.0</td>
<td>78</td>
<td>222.2 ± 3.8</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs10908821</td>
<td>GG</td>
<td>780</td>
<td>235.7 ± 1.6</td>
<td>0.353</td>
<td>0.412</td>
<td>670</td>
<td>241.5 ± 1.7</td>
<td>0.011</td>
<td>0.414</td>
</tr>
<tr>
<td></td>
<td>GC</td>
<td>237</td>
<td>240.5 ± 3.1</td>
<td>189</td>
<td>242.0 ± 3.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>GG</td>
<td>23</td>
<td>231.8 ± 11.0</td>
<td>13</td>
<td>218.6 ± 7.6</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>HDL cholesterol</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs3813609</td>
<td>GG</td>
<td>393</td>
<td>48.4 ± 0.7</td>
<td>0.122</td>
<td>0.097</td>
<td>359</td>
<td>63.0 ± 0.9</td>
<td>0.427</td>
<td>0.397</td>
</tr>
<tr>
<td></td>
<td>GC</td>
<td>490</td>
<td>50.4 ± 0.7</td>
<td>419</td>
<td>62.9 ± 0.8</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CC</td>
<td>170</td>
<td>50.1 ± 1.1</td>
<td>107</td>
<td>65.0 ± 1.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>TT</td>
<td>111</td>
<td>49.2 ± 1.5</td>
<td>104</td>
<td>65.0 ± 1.7</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs2774279</td>
<td>GG</td>
<td>586</td>
<td>48.9 ± 0.6</td>
<td>0.090</td>
<td>0.395</td>
<td>515</td>
<td>63.0 ± 0.7</td>
<td>0.836</td>
<td>0.594</td>
</tr>
<tr>
<td></td>
<td>GC</td>
<td>391</td>
<td>50.8 ± 0.8</td>
<td>319</td>
<td>63.4 ± 0.9</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CC</td>
<td>73</td>
<td>48.0 ± 1.7</td>
<td>49</td>
<td>64.3 ± 2.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs3737787</td>
<td>GG</td>
<td>551</td>
<td>50.2 ± 0.7</td>
<td>0.306</td>
<td>0.128</td>
<td>427</td>
<td>63.9 ± 0.8</td>
<td>0.168</td>
<td>0.503</td>
</tr>
<tr>
<td></td>
<td>GC</td>
<td>418</td>
<td>49.2 ± 0.7</td>
<td>376</td>
<td>61.9 ± 0.9</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CC</td>
<td>86</td>
<td>48.1 ± 1.3</td>
<td>78</td>
<td>64.7 ± 2.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs10908821</td>
<td>GG</td>
<td>780</td>
<td>49.3 ± 0.5</td>
<td>0.074</td>
<td>0.963</td>
<td>670</td>
<td>63.3 ± 0.7</td>
<td>0.892</td>
<td>0.836</td>
</tr>
<tr>
<td></td>
<td>GC</td>
<td>237</td>
<td>50.8 ± 0.9</td>
<td>189</td>
<td>63.3 ± 1.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>GG</td>
<td>23</td>
<td>43.8 ± 3.3</td>
<td>13</td>
<td>61.2 ± 4.3</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>LDL cholesterol</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs3813609</td>
<td>GG</td>
<td>239</td>
<td>150.9 ± 2.8</td>
<td>0.588</td>
<td>0.325</td>
<td>229</td>
<td>154.1 ± 2.9</td>
<td>0.001</td>
<td>0.001</td>
</tr>
<tr>
<td></td>
<td>GC</td>
<td>333</td>
<td>148.4 ± 2.3</td>
<td>280</td>
<td>149.5 ± 2.4</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CC</td>
<td>110</td>
<td>145.3 ± 3.6</td>
<td>81</td>
<td>136.6 ± 3.7</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>TT</td>
<td>120</td>
<td>147.3 ± 2.3</td>
<td>81</td>
<td>136.6 ± 3.7</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CC</td>
<td>310</td>
<td>147.0 ± 2.3</td>
<td>273</td>
<td>147.3 ± 2.5</td>
<td>0.263</td>
<td>0.115</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CT</td>
<td>297</td>
<td>150.0 ± 2.3</td>
<td>247</td>
<td>149.7 ± 2.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>TT</td>
<td>70</td>
<td>150.6 ± 5.7</td>
<td>68</td>
<td>157.5 ± 5.8</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs1556259</td>
<td>GG</td>
<td>507</td>
<td>149.0 ± 1.8</td>
<td>0.430</td>
<td>0.437</td>
<td>463</td>
<td>151.0 ± 2.0</td>
<td>0.0002</td>
<td>0.021</td>
</tr>
<tr>
<td></td>
<td>GC</td>
<td>156</td>
<td>148.2 ± 3.5</td>
<td>121</td>
<td>144.1 ± 3.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CC</td>
<td>17</td>
<td>137.5 ± 8.6</td>
<td>5</td>
<td>121.3 ± 6.2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs2774279</td>
<td>GG</td>
<td>365</td>
<td>149.5 ± 2.3</td>
<td>0.864</td>
<td>0.671</td>
<td>318</td>
<td>151.3 ± 2.4</td>
<td>0.006</td>
<td>0.045</td>
</tr>
<tr>
<td></td>
<td>GC</td>
<td>265</td>
<td>147.7 ± 2.4</td>
<td>230</td>
<td>149.8 ± 2.7</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CC</td>
<td>48</td>
<td>148.4 ± 5.6</td>
<td>41</td>
<td>134.7 ± 4.7</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>TT</td>
<td>53</td>
<td>147.4 ± 6.2</td>
<td>436</td>
<td>149.9 ± 2.0</td>
<td>0.084</td>
<td>0.322</td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs10908821</td>
<td>GG</td>
<td>503</td>
<td>149.0 ± 1.9</td>
<td>0.951</td>
<td>0.824</td>
<td>436</td>
<td>149.9 ± 2.0</td>
<td>0.084</td>
<td>0.322</td>
</tr>
<tr>
<td></td>
<td>CC</td>
<td>162</td>
<td>147.8 ± 3.2</td>
<td>143</td>
<td>148.9 ± 3.6</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>GG</td>
<td>16</td>
<td>149.3 ± 9.9</td>
<td>12</td>
<td>132.5 ± 7.6</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Means and s.e.m.s are given; P values are shown for the nominal and the additive model; all models were adjusted for age and survey; after correction for multiple testing the associations with decreased LDL cholesterol remain statistically significant (P<0.003) in women; LDL cholesterol was measured only in S2 and S3.
incident T2DM, with the only exception for female heterozygotes of rs3737787, who demonstrated a ~30% decreased risk for the development of T2DM during a 10-year follow-up period. Furthermore, haplotypes which were inferred from these particular SNPs, reflected the results of single SNP-outcome analyses, revealing no associations with incident T2DM. Moreover, the polymorphisms rs1556259 and rs3813609 showed significant associations in the nominal model with decreased LDL cholesterol in women after correction for multiple testing. One of the associated SNPs (rs3813609) causes an amino acid exchange (Leu > Val). In haplotype analyses, a weak association with LDL cholesterol was found for two haplotype variants with frequency of more than 10%. No relation was seen in men and none of the analyzed SNPs and haplotypes was significantly associated with TC and HDL cholesterol in our population-based case–cohort study after accounting for multiple testing. The sex-specific differences, observed in the present analyses, are in accordance with several reports from the literature demonstrating sex-specific results for genetic variants within the USF1 gene and lipid markers (18, 21, 23), whereas in other studies, only men were analyzed (28, 41). Also for the association between USF1 and cardiovascular disease and mortality, sex-specific results were found (42). Lee et al. found an association between BMI and USF1 polymorphisms (27) only in women. Mechanisms for sex-specific differences are unknown, although it is known that hormonal differences could play a role.

In this study, a significantly inverse association between one USF1 polymorphism (rs3737787) and incident T2DM was found only in female heterozygotes. This finding is consistent with a Chinese family study, in which the same polymorphism (rs3737787) was associated with T2DM (43). In female US Whites with CAD, SNP rs3737787 was associated with higher glucose levels (18), while in our study, this USF1 SNP was associated with decreased risk of incident T2DM. However, in a multiethnic study, there was no evidence that genetic variants in the USF1 gene may contribute to T2DM susceptibility (24). In contrast to our study, in this report, prevalent T2DM was analyzed. Also in French Caucasians (26) and in a Chinese population study (43), none of the USF1 polymorphisms was associated with T2DM.

Our study supports the previously published results on the association between USF1 polymorphisms and LDL cholesterol. In Dutch FCHL families, suggestive associations for the USF1 polymorphisms rs3737787 and rs2073658 as well as haplotypes were found for small-dense LDL cholesterol (44). A study in Utah families also showed significant associations between the most common USF1 polymorphism rs3737787 and LDL cholesterol, whereas the association was more evident when only males were analyzed (23). In European-Americans, the minor T allele of SNP rs3737787 was associated with lower LDL cholesterol, but there was no evidence that there are sex-specific differences (25). In a Swedish male cohort, the minor allele of rs2073658 highly correlated with rs3737787 was associated with higher LDL cholesterol levels (28).

By contrast, a population-based Korean study and the EARSII study found no association between LDL cholesterol and genetic variants within the USF1 gene, but there was indication of interaction between genetic variants in the USF1 gene and fasting LDL cholesterol (27, 29).

No significant associations between various USF1 polymorphisms or haplotypes, inferred from these SNPs and TC and HDL cholesterol concentrations, were found in our study, which again is in agreement with most published studies so far (18, 24, 26, 27, 29). In Dutch FCHL families, genetic variants within the USF1 gene were associated with TC (18, 44). In addition to TC, HDL, and LDL cholesterol, serum triglycerides were also found to be associated with genetic variants within the USF1 gene in several studies (18, 21–24). However, because of the non-fasting status of our participants, we were not able to investigate serum triglycerides. In vitro tests showed that polymorphisms in the USF1 gene are associated with an increase in lipolytic activity (45, 46) and have a functional role (20). Both association studies and in vitro tests strengthen the associations between the USF1 gene and the lipid parameters.

In contrast to Coon et al. we found significant results for LDL cholesterol in women but not in men (23). Although it is well known that men more often suffer from dyslipidemia than women and associations between polymorphisms within the USF1 gene and serum triglycerides in men were reported, our results in women give evidence that also in female genetic variants within the USF1 gene might play a role for lipid metabolism.

Our study is the first population-based case–cohort study that analyzed the association between genetic variants in the USF1 gene and TC, HDL, and LDL cholesterol in German Caucasians. The prospective study design with incident T2DM cases, the long follow-up period and the large sample size represent the strengths of this study. The systematic genetic dissection of the USF1 gene and the complete coverage of the whole gene locus confirm our conclusions concerning the significant associations between the gene and LDL cholesterol. Nevertheless, the number of subjects homozygous for the minor allele was very small in the case of rs1556259 and the power to detect significant associations between SNPs and incident T2DM might be not sufficient in women due to low case numbers especially for low genotype frequencies. Furthermore, the incidence of T2DM might be underestimated because of the self-reported diabetes and the missing glucose tolerance test.

In conclusion, there is some evidence that genetic variants within the USF1 gene are associated with LDL.
cholesterol and incident T2DM in German Caucasians. The significant results only in women suggest that there are sex-specific differences. Further population-based studies are needed in order to replicate our results and to produce more consistent data.

Declaration of interest

The authors declare that there is no conflict of interest that would prejudice the impartiality of this work.

Funding

The MONICA/KORA Augsburg cohort study was financed by the Helmholtz Center Munich, German Research Center for Environmental Health and supported by grants from the Federal Ministry of Education and Research. The present study was funded by the German Research Foundation (DFG, TH-784/2-1) and the German Federal Ministry of Education, Science, Research and Technology (National Genome Research Net-2) and was supported by the Munich Center of Health Sciences (McHealth) as part of LMUinnovativ.

Acknowledgements

We thank all members of the Helmholtz Center Munich, Institute of Epidemiology, who were involved in the planning and conduct of the MONICA/KORA Augsburg studies, and the KORA Augsburg team. Furthermore, we are grateful to Prof. Lloyd Chambless (School of Public Health, University of North Carolina at Chapel Hill, NC, USA) for statistical advice concerning the analysis of the case-cohort dataset and to Melanie Kolz (Helmholtz Center Munich) for advice regarding the genotyping. Finally, we are indebted to all study participants.

References

10 Botma G, Verhoeven AJ & Jansen H. Hepatic lipase promoter activity is reduced by the C480T and G216A substitutions present in the common LIPC gene variant, and is increased by upstream stimulatory factor. *Atherosclerosis* 2001 **154** 625–632.

www.eje-online.org


26 Gibson F, Hercberg S & Froguel P. Common polymorphisms in the USF1 gene are not associated with type 2 diabetes in French Caucasians. *Diabetes* 2005 **54** 3040–3042.


Received 16 June 2008
Accepted 30 June 2008